Last checked at 
(Sharecast News) - US pharmaceutical giant Merck has penned an agreement with researchers at IAVI to develop a vaccine candidate against the novel coronavirus which provokes Covid-19 using the same underlying technology as the ERVEBO vaccine for the Ebola virus.
Merck's ERVEBO employs recombinant vesicular stomatitis virus (rVSV) technology and was the first such vaccine approved for use against Ebola.
Initial funding would be provided by the US government's Biomedical Advanced Research and Development Authority, the American company said.
"Merck and IAVI are eager to combine our respective strengths to accelerate development of an rVSV vaccine candidate, with the goal of blunting the trajectory of the COVID-19 pandemic," said Merck Research Labs president, Dr. Roger Perlmutter.
"We believe an rVSV-based vaccine strategy represents a promising approach to combating the novel coronavirus pandemic and look forward to implementing an accelerated development program, together with Merck, to evaluate the potential of our vaccine candidate against SARS-CoV-2."
The vaccine candidate would be designed and engineered by scientists at IAVI, which boasts a network of clinical research center partners in Africa and India.
If approved, the two organisations said that they would work to make it accessible and affordable globally.
As of 1234 GMT, shares of Merck were trading 3.31% higher at $78.83.
4 Apr 2024 13:09
UK shareholder meetings calendar - next 7 days
| Friday 5 April | |
| Faron Pharmaceuticals Ltd | AGM |
| VPC Specialty Lending Investments PLC | GM re capital return via B share scheme |
| Monday 8 April | |
| Premier African Minerals Ltd | AGM |
| Tuesday 9 April | |
| Ethernity Networks Ltd | EGM re board appointments and option grants |
| Wednesday 10 April | |
| Valereum PLC | AGM |
| Wincanton PLC | GM re takeover by GXO Logistics Inc |
| Thursday 11 April | |
| AstraZeneca PLC | AGM |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
